Based on our previous data on alterations of GPR17 expression in MS pathogenesis and remyelination failure, we suggest that these functional and mechanistic insights may inspire new pharmacological and therapeutic approaches for the cure of neurodegenerative diseases. Here, GPR17 is linked to myeloid sarcoma.